Kolexia
Curtit Elsa Oncologie médicale
Curtit Elsa
Oncologie médicale
Hôpital Jean-Minjoz
Besançon, France
109 Activités
106 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Récidive tumorale locale Tumeurs du cerveau Prédisposition génétique à une maladie Carcinomes Seconde tumeur primitive Glioblastome Néphrocarcinome

Collaborateurs

Voir plus
Pivot Xavier
Pivot Xavier
Centre Paul Strauss, Strasbourg, France
Mansi Laura
Mansi Laura
Hôpital Jean-Minjoz, Besançon, France
Chaigneau Loic
Chaigneau Loic
Le Mittan Annexe Du Hnfc, Montbéliard, France
Bazan Fernando
Bazan Fernando
Le Mittan Annexe Du Hnfc, Montbéliard, France

Industries

Voir plus
Novartis
24 collaboration(s)
Dernière en 2023
AstraZeneca
12 collaboration(s)
Dernière en 2022
Daiichi Sankyo
3 collaboration(s)
Dernière en 2023
CanceroDigest
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
The French National College of Oncology Teachers (CNEC): Missions, organization, and projects.
Bulletin du cancer   06 janvier 2024
FREDO-ODX-23: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy
Essai Clinique (CHU Besançon)   14 décembre 2023
477P Do ESR1-related mutations generate neoantigens in hormone-receptor-positive HER2-negative metastatic breast cancer?
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
HER2CLIMB: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Essai Clinique (Seagen)   26 juillet 2023
Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis.
Frontiers in oncology   23 juin 2023
Prognosis factors for long-term eribulin response in a cohort of patients with HER2-negative metastatic breast cancer.
2023 ASCO Annual Meeting I   31 mai 2023
A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study.
BMC cancer   17 mai 2023
Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis
13th European Breast Cancer Conference (EBCC-13)   01 novembre 2022
Retrospective thorough analysis of regional lymph node recurrence in breast cancer patients (REASON Trial)
13th European Breast Cancer Conference (EBCC-13)   01 novembre 2022